Fate Therapeutics Inc
FATE- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001434316
In the last 90 days, Fate Therapeutics Inc insiders filed 0 open-market purchases and 2 sales; 156 institutions reported holding it in 13F filings for Q2 2026, worth $193.2M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Fate Therapeutics Inc changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Of which not filed for Q2 2024 | Q2 2024 | Change |
|---|---|---|---|---|
| Holders | 167 | 1 | 182 | +16 |
| Shares | 123.2M | 1 | 122.3M | −886.5K (−0.7%) |
| Value | $904.0M | $0 | $401.1M | −$502.9M (−55.6%) |
1 institution that held it in Q1 2024 haven't filed for Q2 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (38)
Institutions that held Fate Therapeutics Inc at the end of Q2 2024 but not at the end of Q1 2024.
Sold out (22)
Institutions that held Fate Therapeutics Inc at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Suvretta Capital Management, LLC | 2,562,852 | $18.8M |
| Holocene Advisors, LP | 2,527,747 | $18.6M |
| Point72 Asset Management, L.P. | 1,584,300 | $11.6M |
| Schonfeld Strategic Advisors LLC | 886,925 | $6.51M |
| Hudson Bay Capital Management LP | 460,000 | $3.38M |
| Trexquant Investment LP | 257,716 | $1.89M |
| Mirae Asset Global Investments Co., Ltd. | 58,835 | $355.7K |
| Royce & Associates LP | 43,399 | $318.5K |
| American International Group, Inc. | 41,767 | $306.6K |
| Bayesian Capital Management, LP | 39,800 | $292.1K |
| TD Asset Management Inc | 25,000 | $183.5K |
| Inceptionr LLC | 23,343 | $171.3K |
| Raymond James Financial Services Advisors, Inc. | 22,039 | $161.8K |
| Axq Capital, LP | 20,400 | $149.7K |
| Harbor Capital Advisors, Inc. | 19,375 | $142.0K |
| Epiq Partners, LLC | 10,071 | $73.9K |
| Metropolitan Life Insurance Co | 4,590 | $33.7K |
| Quarry LP | 3,000 | $22.0K |
| Group One Trading, L.P. | 1,050 | $7.71K |
| Comerica Bank | 879 | $6.45K |
| Versant Capital Management, Inc | 83 | $609 |
| Nelson, Van Denburg & Campbell Wealth Management Group, LLC | 17 | $124 |
Not filed for Q2 2024 yet (1)
Institutions that held Fate Therapeutics Inc at the end of Q1 2024 and haven't filed a 13F for Q2 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Shell Asset Management Co | 1 | $0 |